In early stage type 2 diabetes patients, the plasma nesfatin-1 levels were increased when compared with those in healthy controls, and reportedly decreased in type 2 diabetes patients receiving antidiabetic treatment (Zhai et al., 2017). This evidence concerns the gene NUCB2 and type 2 diabetes mellitus.